HLS Therapeutics Inc faces a notable downturn, closing down 2.35% in the latest trading session.
In the most recent trading session, HLS Therapeutics Inc (HLS.TO) experienced a decline of 2.35%, closing at CA$4.16. This drop adds to the company's recent challenges as it struggles to maintain investor confidence amid fluctuating financial results.
Investor takeaway: Investors should closely monitor HLS Therapeutics' performance and consider potential underlying issues affecting its stock price, particularly in light of its recent financial results.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.26
+76.2% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc Market Cap: CA$135.1 Million
With a market cap of CA$135.1 million and a profit margin of -18.46%, HLS Therapeutics is facing significant financial hurdles that could impact its future performance.
Bull case
Despite the current downturn, HLS Therapeutics has seen growth in net sales for its key product, Vascepa. This suggests there might be potential for recovery ahead.
Bear case
The stock's decline could signal deeper issues, such as inconsistent revenue growth and negative profit margins, which may discourage investors.
Advertisement
Recent Performance Overview
HLS Therapeutics Inc saw its stock price drop by 2.35% in the latest trading session, closing at CA$4.16. This decline is particularly concerning given the company's recent financial reports, which have shown inconsistent revenue growth and a negative profit margin.
Market Reactions and Investor Sentiment
The recent performance of HLS Therapeutics has raised questions among investors. The company's market cap stands at CA$135.1 million, and with a profit margin of -18.46%, there are growing concerns about its ability to generate sustainable profits. Investors should consider these factors when evaluating their positions in HLS.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
